CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
CMOs showed an increasing reluctance to take on debt in 2022
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Subscribe To Our Newsletter & Stay Updated
